The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.50
Bid: 35.50
Ask: 36.50
Change: -0.50 (-1.39%)
Spread: 1.00 (2.817%)
Open: 36.00
High: 35.50
Low: 35.50
Prev. Close: 36.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

1 Aug 2018 13:24

RNS Number : 5083W
Creo Medical Group PLC
01 August 2018
 

1 August 2018

Creo Medical Group plc

("Creo" or the "Company")

 

Result of General Meeting

 

Creo Medical Group plc (AIM: CREO) is pleased to announce that, at the General Meeting held today, all resolutions were duly passed by means of a poll vote. The total number of votes received for each resolution is set out below:

 

Resolution No.

Votes for

Votes against

Votes total

Votes withheld

01

63,639,528 (94.09%)

 

3,995,278 (5.91%)

67,634,806 (83.37%)

625,000

02

63,639,528 (94.09%)

 

3,995,278 (5.91%)

67,634,806 (83.37%)

625,000

03

63,639,528 (93.23%)

4,620,278 (6.77%)

68,259,806 (84.14%)

 

0

 

The Company confirms that, conditional on Admission becoming effective, it has allotted and issued 4,000,000 new Ordinary Shares pursuant to the EIS/VCT Placing. It is expected that the EIS/VCT Placing Shares will be admitted to AIM with effect from 8.00am tomorrow, 2 August 2018.

 

Further details regarding the Placing and the Placing Shares can be found in the announcement issued by the Company on 13 July 2018 and in the Circular posted to Shareholders on that same day, which are available to view on the Company's website: investors.creomedical.com. Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.

 

Following Admission of the EIS/VCT Placing Shares, the Company's issued ordinary share capital will consist of 85,123,065 Ordinary Shares; no shares are held in treasury. The above figure of 85,123,065 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The Additional EIS/VCT Placing is conditional on receipt of the Additional VCT Advanced assurance by the Company. Whilst the Non EIS/VCT Placing is not conditional the receipt of the Additional VCT Advanced Assurance, the allotment and Admission of the Non EIS/VCT Shares cannot take place before the allotment of the Additional EIS/VCT Shares.

 

As the Additional VCT Advanced Assurance has not yet been obtained, the issue of the Additional EIS/VCT Shares and the Non EIS/VCT Shares has been delayed. Admission of the Additional EIS/VCT Shares and Non EIS/VCT Shares will occur on the third Business Day following receipt of Additional VCT Advanced Assurance.

 

In the event that the Additional VCT Advanced Assurance is not received before the Long Stop Date of 13 September 2018 (or at such time as HMRC has informed the Company that such approval will not be obtained), then the Additional EIS/VCT Placing will not complete, but the Non EIS/VCT Placing will complete, the Non EIS/VCT Shares will be issued and Admission of the Non EIS/VCT Shares will take place at latest on the Long Stop Date.

 

Contacts

 

Creo Medical:

+44 (0)129 160 6005

Richard Rees

Cenkos:

+44 (0)207 397 8900

Camilla Hume / Mark Connelly (NOMAD)

Michael Johnson / Russell Kerr (Sales)

FTI Consulting:

+44 (0)203 727 1000

Brett Pollard / Mo Noonan

creo@fticonsulting.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMSSEFEFFASEEA
Date   Source Headline
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.